ADMA Biologics, Inc. (ADMA)
Automate Your Wheel Strategy on ADMA
With Tiblio's Option Bot, you can configure your own wheel strategy including ADMA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating
Published: April 01, 2026 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, April 01, 2026 (GLOBE NEWSWIRE) -- Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) saw the price of their shares slide over 16% on March 24, 2026 on short seller Culper Research's report, “ADMA Biologics Inc. (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and -3.5% Real Growth in 2025 vs. +20% Reported.
Read More
Will Lead Drug Asceniv Fuel ADMA's Top-Line Growth in 2026?
Published: April 01, 2026 by: Zacks Investment Research
Sentiment: Positive
ADMA rides on surging Asceniv demand, expanding payer coverage, and stronger plasma supply deals to drive rapid revenue growth through 2027.
Read More
ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating
Published: March 30, 2026 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO, March 30, 2026 /PRNewswire/ -- Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) saw the price of their shares slide over 16% on March 24, 2026 on short seller Culper Research's report, "ADMA Biologics Inc. (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and -3.5% Real Growth in 2025 vs. +20% Reported.
Read More
Why Is Adma Biologics (ADMA) Down 45.4% Since Last Earnings Report?
Published: March 27, 2026 by: Zacks Investment Research
Sentiment: Negative
Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock?
Read More
ADMA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Stockholders and Encourages Investors to Contact the Firm
Published: March 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In ADMA To Contact Him Directly To Discuss Their Options
Read More
Did You Suffer Losses in ADMA Biologics, Inc. (ADMA)? Contact Levi & Korsinsky About Securities Fraud Claims
Published: March 27, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - March 27, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ: ADMA) concerning potential violations of the federal securities laws. On the Q4 2025 earnings call, CEO Adam Grossman stated "ASCENIV achieved $363 million in net revenue, representing 51% year-over-year growth.
Read More
Short Seller Report Alleges ADMA Biologics Financial Misrepresentation
Published: March 25, 2026 by: Benzinga
Sentiment: Negative
• ADMA Biologics stock is testing key support levels. What's pressuring ADMA?
Read More
Down 27% in 4 Weeks, Here's Why Adma Biologics (ADMA) Looks Ripe for a Turnaround
Published: March 25, 2026 by: Zacks Investment Research
Sentiment: Positive
The heavy selling pressure might have exhausted for Adma Biologics (ADMA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read More
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?
Published: March 19, 2026 by: Zacks Investment Research
Sentiment: Neutral
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Adma Biologics (ADMA) Upgraded to Strong Buy: Here's Why
Published: March 03, 2026 by: Zacks Investment Research
Sentiment: Positive
Adma Biologics (ADMA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?
Published: March 03, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
ADMA Q4 EPS Up 14% Y/Y, Revenues Gain From Strong Asceniv Performance
Published: February 26, 2026 by: Zacks Investment Research
Sentiment: Positive
ADMA posts 18% Q4 revenue growth as Asceniv drives record 2025 sales, with 2026 revenues seen topping $635M and margins set to expand.
Read More
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Neutral
In the closing of the recent trading day, Adma Biologics (ADMA) stood at $17.5, denoting a +1.16% move from the preceding trading day.
Read More
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?
Published: January 29, 2026 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
ADMA Gains 13.8% in Three Months: More Upside Potential for 2026?
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Positive
ADMA shares rose 13.8% over three months as demand for Asceniv surged, driving higher 2026 revenues and EBITDA targets amid margin expansion.
Read More
ADMA Biologics: Business Update And My Price Target
Published: January 14, 2026 by: Seeking Alpha
Sentiment: Neutral
ADMA Biologics was trading poorly in early 2021, near $2 per share. My thesis centered on ADMA's asset value, including plasma centers, matching its enterprise value. Strong revenue growth, insider buying, and a poison pill signaled management's confidence in profitability.
Read More
ADMA Biologics Reports Preliminary 2025 Results, Ups 2026 Outlook
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
ADMA expects 2025 revenues of approximately $510-$511 million, raising 2026 guidance on strong Asceniv demand and margin expansion.
Read More
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?
Published: December 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Adma Biologics (ADMA) and Artivion (AORT) have performed compared to their sector so far this year.
Read More
Adma Biologics (ADMA) Up 43.3% Since Last Earnings Report: Can It Continue?
Published: December 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock?
Read More
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
Published: December 01, 2025 by: Zacks Investment Research
Sentiment: Negative
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Wall Street Analysts Think Adma Biologics (ADMA) Could Surge 60.24%: Read This Before Placing a Bet
Published: November 27, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 60.2% upside potential for Adma Biologics (ADMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Adma Biologics (ADMA) Upgraded to Buy: Here's What You Should Know
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Adma Biologics (ADMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Is ADMA Biologics (ADMA) Outperforming Other Medical Stocks This Year?
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Adma Biologics (ADMA) and Cronos Group (CRON) have performed compared to their sector so far this year.
Read More
Adma Biologics (ADMA) Recently Broke Out Above the 200-Day Moving Average
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Positive
After reaching an important support level, Adma Biologics (ADMA) could be a good stock pick from a technical perspective. ADMA surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.
Read More
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?
Published: November 14, 2025 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
Adma Biologics (ADMA) Just Flashed Golden Cross Signal: Do You Buy?
Published: November 12, 2025 by: Zacks Investment Research
Sentiment: Positive
From a technical perspective, Adma Biologics (ADMA) is looking like an interesting pick, as it just reached a key level of support. ADMA recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
Read More
Adma Biologics (ADMA) Crossed Above the 50-Day Moving Average: What That Means for Investors
Published: November 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Adma Biologics (ADMA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ADMA broke through the 50-day moving average, which suggests a short-term bullish trend.
Read More
Wall Street Analysts Believe Adma Biologics (ADMA) Could Rally 108.5%: Here's is How to Trade
Published: November 11, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 108.5% upside potential for Adma Biologics (ADMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Positive
ADMA Biologics posts strong Q3 revenues and record Asceniv demand, but shares slip as higher taxes temper net income growth.
Read More
About ADMA Biologics, Inc. (ADMA)
- IPO Date 2013-10-17
- Website https://www.admabiologics.com
- Industry Biotechnology
- CEO Adam S. Grossman
- Employees 685